Sunshine Biopharma Inc.

XNAS

Last traded price · USD

$2.61

−1.51%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.65
Volume: 1,400
Day's high: —
Day's low: —

In brief

Sunshine Biopharma Inc. is a US-listed company listed on Nasdaq, valued at about $2M.
Its shares closed at $2.65 on 4 Nov 2026, down 99.2% over the past year.
From India you can buy SBFM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Sunshine Biopharma Inc. (SBFM) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole SBFM share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade SBFM options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

2.7% above its 52-week low
Closed at $2.65 on 4 Nov 2026: 99.4% below the 52-week high of $464.00 (18 May 2026) and 2.7% above the low of $2.58 (26 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Behind SPY over 1 year
1 month: −66.7% (SPY −1.6%). 3 months: −90.0% (SPY −0.4%). 1 year: −99.2% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SBFM, SPY · as of 4 Nov 2026
Short interest at 110.5% of shares outstanding
840.9K shares were sold short at the 15 Oct 2026 settlement, 110.5% of the 761.0K shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $2.65 was 79.5% below its 50-day average ($12.94) and 97.5% below its 200-day average ($105.44). It has closed below the 200-day for 245 sessions, since 13 Nov 2025. The 50-day average crossed below the 200-day on 31 Dec 2025, 212 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 26.6, 30 or below
The 14-session relative strength index closed at 26.6 on 4 Nov 2026, its 19th session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−66.7%

6 months−98.8%

1 year−99.2%

Since Nov 5, 2021−100.0%

Newswire

About

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

Website

Notable moves

April 5, 2022
+148.23%
March 9, 2022
+150.00%
February 15, 2022
+5337.26%

Sunshine Biopharma Inc.

XNAS

Last traded price · USD

$2.61

−1.51%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.65
Volume: 1,400
Day's high: —
Day's low: —

In brief

Sunshine Biopharma Inc. is a US-listed company listed on Nasdaq, valued at about $2M.
Its shares closed at $2.65 on 4 Nov 2026, down 99.2% over the past year.
From India you can buy SBFM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Sunshine Biopharma Inc. (SBFM) shares from India?

Do I need the price of a whole SBFM share to invest?

How much can I invest in US stocks in a year?

Can I trade SBFM options or futures?

Insights

Quotes run fifteen minutes behind.

2.7% above its 52-week low
Closed at $2.65 on 4 Nov 2026: 99.4% below the 52-week high of $464.00 (18 May 2026) and 2.7% above the low of $2.58 (26 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Behind SPY over 1 year
1 month: −66.7% (SPY −1.6%). 3 months: −90.0% (SPY −0.4%). 1 year: −99.2% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SBFM, SPY · as of 4 Nov 2026
Short interest at 110.5% of shares outstanding
840.9K shares were sold short at the 15 Oct 2026 settlement, 110.5% of the 761.0K shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $2.65 was 79.5% below its 50-day average ($12.94) and 97.5% below its 200-day average ($105.44). It has closed below the 200-day for 245 sessions, since 13 Nov 2025. The 50-day average crossed below the 200-day on 31 Dec 2025, 212 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 26.6, 30 or below
The 14-session relative strength index closed at 26.6 on 4 Nov 2026, its 19th session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−66.7%

6 months−98.8%

1 year−99.2%

Since Nov 5, 2021−100.0%

Newswire

About

Website

Notable moves

April 5, 2022
+148.23%
March 9, 2022
+150.00%
February 15, 2022
+5337.26%

Sunshine Biopharma Inc.

Sunshine Biopharma Inc. in brief

2.7% above its 52-week low

Behind SPY over 1 year

Short interest at 110.5% of shares outstanding

Below its 50- and 200-day averages

RSI(14) at 26.6, 30 or below

Sunshine Biopharma Inc.

Sunshine Biopharma Inc. in brief

2.7% above its 52-week low

Behind SPY over 1 year

Short interest at 110.5% of shares outstanding

Below its 50- and 200-day averages

RSI(14) at 26.6, 30 or below